

Role of gentamicin in reducing urinary tract infections in patients with neurogenic bladder

Michael S. Floyd Jr, MCh, FRCS (Urol); Rauf N. Khadr, MD

Northwest Regional Spinal Cord Injury Unit, Southport & Ormskirk NHS Foundation Trust, Merseyside, United Kingdom

Cite as: *Can Urol Assoc J* 2017;11(12):427-8. <http://dx.doi.org/10.5489/cuaj.4945>

Published online November 1, 2017

We read with interest the recent study by Cox et al in the September 2017 issue of *CUAJ*.¹ Authors describe a series of 20 neurogenic bladder patients on intermittent self-catheterization treated with intravesical instillations of gentamicin in order to reduce recurrent urinary tract infection (UTI). The authors state that use of intravesical gentamicin reduced the frequency of UTI from four episodes in six months to one in six months. Additionally, less telephone encounters and fewer hospital visits were recorded and other antibiotic usage decreased, with minimal adverse events noted. A secondary aim was to assess microbiological resistance patterns: the rate of overall resistance to gentamicin did not increase.

Of the 20 patients involved, 59.1% were male, and spinal cord injury (SCI) accounted for 63.6% of those included, with 13.6% of patients having multiple sclerosis (MS). The mean age of participants was 37.5 years.

The authors emphasize the reduction in hospitalizations, emergency room visits, and telephone encounters as a result of this novel treatment. Specific to the SCI and MS patients, this is a very important point, as bladder function frequently affects quality of life.² It should be acknowledged by the authors that no validated questionnaire specific to the neurogenic bladder patient was included to assess the quality of life improvement with respect to bladder health after intravesical gentamicin treatment. In our neuro-urology unit, we routinely use the SF Qualiveen questionnaire³ at baseline assessment of all SCI and MS patients in order to determine the impact of bladder symptoms on quality of life pre and post any bladder-specific treatment. One of the

domains tested is “frequency of limitations” and enquires about life being regulated by bladder problems: if intravesical gentamicin reduces hospital visits and UTI, then overall quality of life due to bladder health is presumably better in the neurogenic patient and should be measured objectively.

Additionally, although data pertaining to intravesical gentamicin use is limited in cases of recurrent UTI, case reports exist in the U.K. literature. Naderi et al have reported successful treatment of recalcitrant *E. coli* UTI in an 81-year-old diabetic female with multiple allergies following a five-day course of daily intravesical gentamicin.⁴

Finally, although no significant adverse effects were reported, the authors do not address the hypothetical risk of systemic absorption. Whatley et al have reported on the proposed risk of systemic absorption in ENT patients undergoing nasal irrigations with gentamicin.⁵

References

1. Cox L, He C, Bevins J, et al. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. *Can Urol Assoc J* 2017;11:E350-4. <http://dx.doi.org/10.5489/cuaj.4434>
2. Costa P, Perrouin-Verbe B, Colvez A, et al. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. *Eur Urol* 2001;39:107-13. <https://doi.org/10.1159/000052421>
3. Bonniaud V, Bryant D, Parratte B, et al. Development and validation of the short form of a urinary quality of life questionnaire: SF-Qualiveen. *J Urol* 2008;180:2592-8. <https://doi.org/10.1016/j.juro.2008.08.016>
4. Naderi K, Urwin G, Casey RG. Intravesical gentamicin treatment of recurrent Escherichia coli urinary tract infections in a patient with multiple antibiotic allergies. *J Clin Urol* 2014;7:364-6. <https://doi.org/10.1177/2051415813508545>
5. Whatley WS, Chandra RK, MacDonald CB. Systemic absorption of gentamicin nasal irrigations. *Am J Rhinol* 2006;20:251-4. <https://doi.org/10.2500/ajr.2006.20.2855>

Correspondence: Dr. Michael S. Floyd Jr, Department of Reconstructive Urology, St. Helens & Knowsley Hospital, Liverpool, United Kingdom; michaelfloyd@nhs.net

Author reply

Anne P. Cameron, MD, FRCSC, FPMRS
Department of Urology, University of Michigan, Ann
Arbor, MI, United States

In response to the above letter to the editor, we do agree that a validated quality of life questionnaire would significantly have enhanced these findings since we only have anecdotal evidence of the improved quality of life with the reduction in urinary tract infections (UTIs). As a result of this lack of objective data, in our future prospective work, we plan to employ the UTI-specific questionnaire authored by Tulskey et al¹ that measures quality of life in spinal cord injury and also has a specific bladder complications scale.

Gentamicin absorption has been studied in animal and human work at our institution.² Ten children, many with augmentation cystoplasties or vesicoureteric reflux, which potentially could have increased absorption over a native bladder, had serum gentamicin levels drawn 30 minutes after instillation and none had measurable levels or changes in creatinine during the study. Similar findings were seen in the six study dogs. This study was the basis for ongoing use of this method of prophylaxis at our site. Another study also addressed safety in 80 children receiving chronic gentamicin bladder instillations where half had a prior augmentation cystoplasty. All patients had serum gentamicin levels drawn and none had measurable values.³ Given these negative studies in high-risk populations and the known lack of absorption of gentamicin from the gut and bladder, we do feel that this is a safe therapy with no reported systemic absorption in a human receiving the drug via the bladder.

References

1. Tulskey DS, Kisala PA, Victorson D, et al. Developing a contemporary patient-reported outcomes measure for spinal cord injury. *Arch Phys Med Rehabil* 2011;92:S44-51. <https://doi.org/10.1016/j.apmr.2011.04.024>
2. Wan J, Kozminski M, Wang SC, et al. Intravesical instillation of gentamicin sulfate: In vitro, rat, canine, and human studies. *Urology* 1994;43:531-6. [https://doi.org/10.1016/0090-4295\(94\)90249-6](https://doi.org/10.1016/0090-4295(94)90249-6)
3. Defoor W, Ferguson D, Mashni S, et al. Safety of gentamicin bladder irrigations in complex urological cases. *J Urol* 2006;175:1861-4. [https://doi.org/10.1016/S0022-5347\(05\)00928-6](https://doi.org/10.1016/S0022-5347(05)00928-6)

Correspondence: Dr. Anne P. Cameron, Department of Urology, University of Michigan, Ann Arbor, MI, United States; annepell@med.umich.edu

XGEVA®
(denosumab)

Indication and clinical use:

- XGEVA is indicated for reducing the risk of developing skeletal-related events (SREs) in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumours.
- Not indicated for reducing the risk of developing skeletal-related events in patients with multiple myeloma.
- Not indicated for reducing the risk of developing skeletal-related events in pediatric patients.

Contraindication:

- XGEVA is contraindicated in patients with pre-existing hypocalcemia, which must be corrected prior to initiating therapy.

Most serious warnings and precautions:

Osteonecrosis of the jaw (ONJ): In clinical trials, the incidence of ONJ was higher with longer duration of exposure. In patients with risk factors for ONJ, an individual risk/benefit assessment should be performed before initiating therapy with XGEVA. An oral exam should be performed and a dental exam with appropriate preventive dentistry is recommended prior to treatment with XGEVA, especially in patients with risk factors for ONJ. Avoid invasive dental procedures while receiving XGEVA. In patients who develop ONJ during treatment with XGEVA, a temporary interruption of treatment should be considered based on individual risk/benefit assessment until the condition resolves.

Other relevant warnings and precautions:

- Do not use concurrently with Prolia®
- Do not use concurrently with bisphosphonates
- Hypocalcemia has been reported (including severe symptomatic hypocalcemia and fatal cases). Monitor calcium prior to the initial dose, within two weeks after the initial dose, and if suspected symptoms of hypocalcemia occur. Administer adequate calcium, vitamin D, and magnesium, as necessary. If hypocalcemia occurs while receiving XGEVA, additional short-term calcium supplementation and additional monitoring may be necessary.
- Caution on risk of hypocalcemia and accompanying increases in parathyroid hormone in patients with renal impairment
- Clinically significant hypercalcemia has been reported in XGEVA-treated patients with growing skeletons weeks to months following treatment discontinuation. Monitor patients for signs and symptoms of hypercalcemia and treat appropriately.
- Skin infections
- Hypersensitivity reactions including anaphylaxis
- Atypical femoral fractures
- Not recommended for use in pregnant women. Women should not become pregnant during treatment and for at least 5 months after the last dose of XGEVA.
- For nursing women, it is not known whether XGEVA is excreted into human milk.

For more information:

Please consult the Product Monograph at http://www.amgen.ca/Xgeva_PM.pdf for important information relating to adverse reactions, drug interactions, and dosing that have not been discussed here.

The Product Monograph is also available by calling Amgen Medical Information at 1-866-502-6436.

Fizazi et al. study²

Phase 3, randomized, double-blind, double-dummy, active-controlled study. Patients with castrate-resistant prostate cancer and bone metastases (n=1901) received either 120 mg XGEVA® SC Q4W (once every 4 weeks) (n=950) or 4 mg zoledronic acid IV Q4W (n=951). The primary outcome measure was to demonstrate non-inferiority of time to first on-study SRE as compared to zoledronic acid. The secondary outcome measures were superiority of time to first on-study SRE and superiority of time to first and subsequent SREs. An SRE is defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone or spinal cord compression.

References:

1. XGEVA® Product Monograph, Amgen Canada, 2016.
2. Fizazi K, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. *Lancet*. 2011;377(9768):813-822.

AMGEN®
Oncology

© 2017 Amgen Canada Inc.
All rights reserved.

